A Risk-Benefit Assessment of Losartan Potassium in the Treatment of Hypertension
- 1 January 1997
- journal article
- review article
- Published by Springer Nature in Drug Safety
- Vol. 16 (1), 56-65
- https://doi.org/10.2165/00002018-199716010-00004
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- The angiotensin II type 1 receptor antagonists. A new class of antihypertensive drugs.1995
- Effects of Losartan on a Background of Hydrochlorothiazide in Patients With HypertensionHypertension, 1995
- Antihypertensive efficacy and tolerability of once daily losartan potassium compared with captopril in patients with mild to moderate essential hypertensionJournal Of Hypertension, 1995
- Beyond ACE inhibition: new developments in drug therapy for hypertensionThe Medical Journal of Australia, 1995
- Evolution of blockade of the renin-angiotensin system.1995
- Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members.1995
- Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease.1994
- Is the antiproteinuric effect of ACE inhibition mediated by intereference in the renin-angiotensin system?Kidney International, 1994
- Effect of Antihypertensive Therapy on the Kidney in Patients with Diabetes: A Meta-Regression AnalysisAnnals of Internal Medicine, 1993
- Hypotensive Effect of Losartan, a Nonpeptide Angiotensin II Receptor Antagonist, in Essential HypertensionAmerican Journal of Hypertension, 1993